CompletedNCT02039908
Examining Tolerance to CNS Stimulants in ADHD
Medication studyAges 6–12United States
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Listed locations
- MiamiSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 267
- Sponsor
- Florida International University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT02039908
- Official title
Show the full official title
Examining Tolerance to CNS Stimulants in ADHD
Recruitment & locations
CompletedMiami
Questions about this study
Who is behind this study?
The study sponsor is Florida International University, a university.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)